In the presence of the B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600 mutation (40% to 50% of cutaneous melanomas), RAF- and MEK-targeted therapies can be effective for CNS metastatic melanoma in the short to medium term, with a high probability of symptomatic improvement even in people dependent on steroids albeit with a very low probability of long-term disease control and survival 7. This evidence concerns the gene BRAF and cutaneous melanoma.